Vical Inc. (Nasdaq: VICL) reported disappointing results from an ongoing
Phase 1/2 clinical study of its genital herpes vaccine sending the
stock price plummeting 65 cents to $0.77.
Vical reports disappointing study results
June 23, 2015 at 12:04 PM EDT
